Overview
Mutlu Arat practices in Sisli, Turkey. Arat is rated as an Advanced expert by MediFind in the treatment of Hepatic Venoocclusive Disease with Immunodeficiency. Their top areas of expertise are Graft Versus Host Disease (GvHD), Acute Lymphoblastic Leukemia (ALL), Hepatic Venoocclusive Disease with Immunodeficiency, Leukemia, and Bone Marrow Transplant.
Their clinical research consists of co-authoring 93 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 6 articles in the study of Hepatic Venoocclusive Disease with Immunodeficiency.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Acute Lymphoblastic Leukemia (ALL)
- Bone Marrow TransplantArat isDistinguished. Learn about Bone Marrow Transplant.
- Graft Versus Host Disease (GvHD)
- Advanced
- Acute Myeloid Leukemia (AML)
- Hepatic Venoocclusive Disease with Immunodeficiency
- Hodgkin LymphomaArat isAdvanced. Learn about Hodgkin Lymphoma.
- LeukemiaArat isAdvanced. Learn about Leukemia.
- Experienced
- Abdominal Obesity Metabolic Syndrome
- ABO IncompatibilityArat isExperienced. Learn about ABO Incompatibility.
- Adult T-Cell LeukemiaArat isExperienced. Learn about Adult T-Cell Leukemia.
- Anaplastic Large Cell Lymphoma
- Bronchiolitis ObliteransArat isExperienced. Learn about Bronchiolitis Obliterans.
- Chronic Graft Versus Host Disease (cGvHD)